Jeena Sikho Lifecare Limited has delivered outstanding financial performance in Q3FY26, with the ayurvedic healthcare company reporting exceptional growth across all key financial metrics for the quarter ended 31st December 2025. Following these strong results, the company has made available the audio recording of its earnings conference call held on February 9, 2026.

Financial Performance Highlights

The company's financial results demonstrate remarkable improvement, with net profit experiencing substantial growth year-on-year. The strong performance reflects the company's expanding presence in the ayurvedic healthcare sector and effective operational execution.

Nine-Month Performance

For the nine months ended 31st December 2025, the company maintained its strong momentum with significant improvements across all parameters compared to the corresponding period in the previous year.

Segment-wise Performance

The company operates through two primary business segments, both contributing significantly to the overall growth during Q3FY26.

Ayurvedic Products/Medicines Segment:

• Q3FY26 revenue: ₹12,176.52 lacs (vs ₹5,115.23 lacs in Q3FY25)
• Segment result: ₹5,316.32 lacs (vs ₹1,090.21 lacs in Q3FY25)
• Nine-month revenue: ₹29,771.30 lacs (vs ₹14,673.20 lacs)

Ayurvedic Healthcare Services Segment:

• Q3FY26 revenue: ₹9,989.95 lacs (vs ₹6,453.97 lacs in Q3FY25)
• Segment result: ₹4,104.75 lacs (vs ₹1,304.49 lacs in Q3FY25)
• Nine-month revenue: ₹28,808.27 lacs (vs ₹18,308.93 lacs)

Earnings Call and Corporate Communications

Following the announcement of these strong financial results, Jeena Sikho Lifecare Limited conducted an earnings conference call on February 9, 2026, to discuss the Q3FY26 performance with stakeholders. The company has now made the audio recording of this call publicly available on its website, ensuring transparency and accessibility for investors and analysts.

The availability of the earnings call recording demonstrates the company's commitment to maintaining transparent communication with its stakeholders and complying with regulatory requirements under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Corporate Developments and Regulatory Compliance

The company's Board of Directors approved the unaudited standalone and consolidated financial results at their meeting held on February 7, 2026. The Board meeting commenced at 04:05 P.M. (IST) and concluded at 04:35 P.M. (IST). Additionally, the company granted 2,18,875 employee stock options to 1,176 eligible employees under the Jeena Sikho Employee Stock Option Scheme 2025 on January 1, 2026, with an exercise price of ₹2 per option.

Consolidated Results

On a consolidated basis, the company reported net profit of ₹6,659.89 lacs for Q3FY26 compared to ₹1,321.08 lacs in Q3FY25. Consolidated revenue from operations reached ₹22,167.97 lacs versus ₹11,569.20 lacs in the corresponding quarter of the previous year. The consolidated results include the performance of subsidiaries Jeena Green Resources Private Limited and Jeena Sikho International LLC.

Jeena Sikho Lifecare Limited announced that its board of directors approved a significant loan agreement with its wholly owned subsidiary during a meeting held on January 21, 2026. The board meeting, which commenced at 5:30 PM and concluded at 6:00 PM, resulted in the approval of an unsecured loan facility worth AED 7.53 million.

Loan Agreement Details

The loan agreement was executed with Jeena Sikho International LLC, a wholly owned subsidiary of the company, to provide financial assistance for business and operational requirements. The transaction is structured as a related party transaction conducted on an arm's length basis.

Transaction Structure and Terms

The loan facility carries an interest rate of 8.50% per annum, calculated on a simple interest basis on the outstanding principal amount. This interest rate applies uniformly to every tranche disbursed under the agreement. The loan tenure spans five years from the date of the first disbursement, providing the subsidiary with medium-term financial support.

The company holds 100% equity shareholding in Jeena Sikho International LLC, making this transaction a related party arrangement. The board confirmed that the loan agreement was structured and executed on an arm's length basis, ensuring compliance with regulatory requirements for related party transactions.

Regulatory Compliance and Disclosures

The announcement was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company provided comprehensive details as required under the listing regulations and SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024.

Compliance Matters Addressed

The board also acknowledged fines imposed by stock exchanges for previous non-compliance issues. The National Stock Exchange of India Limited imposed a fine dated December 31, 2025, while BSE Limited imposed a fine dated December 15, 2025, both for non-compliance with Regulation 29 of the SEBI listing regulations.

The company has paid both fines in full and implemented measures to strengthen its compliance systems going forward. This demonstrates the company's commitment to maintaining regulatory compliance and improving its governance framework.

Corporate Information

Jeena Sikho Lifecare Limited operates over 120 Ayurveda clinics and hospitals, positioning itself in the traditional healthcare sector. The company is registered in Punjab with its registered office located in Zirakpur and corporate office in New Delhi. The loan agreement supports the expansion and operational requirements of its international subsidiary, facilitating the company's business growth initiatives.